Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7629784 | 0.83 | ALDH1A1 (0.38) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL248738 | 0.81 | CYP3A4 (0.41) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL125935 | 0.81 | CYP3A4 (0.41) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29871279 | 0.79 | CYP3A4 (0.39) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1036031 | 0.79 | CYP3A4 (0.59) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| Phosphine SCHEMBL18982856 | 0.79 | CYP3A4 (0.39) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8722031 | 0.79 | CYP3A4 (0.39) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL566521 | 0.77 | TAS1R3 (0.42) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4981030 | 0.77 | CYP3A4 (0.38) | CYP3A4ACHETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL403704 | 0.77 | CA12 (0.41) | TAS1R3TAS1R1TAS1R2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | claimed |
| US-7045653-B2 | cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension | PFIZER, INC. (US) | 2006-05-16 | — | — | US | claimed |
| EP-1581480-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS | Pfizer Limited (GB) | 2005-10-05 | — | — | EP | claimed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | claimed |
| US-20050075392-A1 | Novel pharmaceuticals | DACK KEVIN NEIL (GB) | 2005-04-07 | — | — | US | claimed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | claimed |
| WO-2004056750-A1 | CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | claimed |
| US-5362902-A | Diuretics and treatment of cardiovascular disorders | PFIZER INC. (US) | 1994-11-08 | — | — | US | claimed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | claimed |
| EP-0274234-B1 | SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1991-09-11 | — | — | EP | claimed |
| WO-1991010644-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | claimed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | claimed |
| WO-1991007378-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-05-30 | — | — | WO | claimed |
| EP-0343911-A2 | Cycloalkyl-substituted glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-29 | — | — | EP | claimed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | claimed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | claimed |
| EP-2170850-B1 | NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2014-09-24 | — | — | EP | disclosed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | disclosed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075392-A1 | Novel pharmaceuticals | MME, ECE1, ECE2 | CYP3A4 1382/4885ACHE 394/4885TAS1R3 3770/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | CYP3A4 1589/4885ACHE 336/4885TAS1R3 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.